Betuvax develops new-generation subunit vaccines based on the proprietary Betusphere carrier against infectious diseases.
The company has developed a series of antigens for vaccines against Covid using which the Betuvax-CoV-2 vaccine was subsequently created in cooperation with RBT, as well as the Combi 5V combined pentavalent influenza and coronavirus vaccine in cooperation with RBT and Nacimbio.
The company also has a number of drugs at earlier development stages: preventative, therapeutic HPV, rotavirus, and allergy vaccines.
The research is carried out using grants from the Skolkovo Foundation.
In 2022, it was a finalist in the Moscow Mayor’s “Innovator of Moscow” award.
In 2021, it received the “Technological Breakthrough 2021” award (NTI platform).
Platform for developing corpuscular adjuvant-based recombinant protein vaccines. The use of an adjuvant for betulin-based vaccines makes it possible to increase immunogenicity (efficacy, protectiveness), the speed of development and duration of the immune response, optimize the antigen dose, and prevent competition of antigens in combination vaccines.
Primary/booster vaccination SARS-COV-2
Russia’s first subunit recombinant vaccine based on spherical particles with the surface protein of coronavirus.
The antigen used is part of the RBD domain of the S protein of coronavirus SARS-CoV-2. It is the RBD domain in response to which the immune system produces the largest number of virus-neutralizing antibodies.
The Betuvax-CoV-2 vaccine does not contain inactivated or weakened particles of the new SARS-COV-2 coronavirus, does not contain vector viruses (adenovirus, influenza, measles, etc.), does not contain genetic material (RNA or DNA), inorganic adjuvants, so it is designed as a tool for multiple revaccinations, since it potentially does not have any short-term adverse reactions and does not cause excessive antigenic load.
The Betuvax-CoV-2 vaccine is designed so that it can be quickly optimized for new strains of coronavirus.
Influenza vaccination
Quadrivalent subunit influenza vaccine consisting of surface antigens of the influenza virus adsorbed on the adjuvant surface. The drug does not contain preservatives or stabilizing agents that could cause post-vaccination complications.
The vaccine showed a high safety profile and low reactogenicity in preclinical and clinical trials due to its low antigen content (one vaccine dose contains 5 μg of hemagglutinin from each of the four seasonal vaccine strains).
Influenza + COVID-19 Combi vaccine
Combined recombinant vaccine for protection against four seasonal strains of influenza viruses, as well as a component protecting against the SARS-CoV-2 virus.
The vaccine was developed on the basis of the TetraFluBet and Betuvax-CoV-2 vaccines.
Immunomodulator
The company began developing a substance with immunobiological activity. Preclinical studies are currently being completed.
HPV vaccination
Allergies
